MELA Sciences Reports First Quarter 2015 Financial Results

Irvington, New York, UNITED STATES

IRVINGTON, N.Y., May 14, 2015 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® System, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional information to help them decide whether or not to biopsy (at the most curable and cost-effective stage), today reported financial results for the quarter ended March 31, 2015.

First Quarter 2015 Financial Results Compared with First Quarter 2014 Results:

  • Revenue totaled approximately $0.1 million, unchanged compared with a year ago. The Company has taken steps to obtain medical reimbursement and on March 9, 2015, the CPT® Editorial Panel assigned additional Category III codes that apply to the MelaFind System, which should become effective January 1, 2016. These codes provide the basis for pursuing third party and CMS insurance coverage for MelaFind.  Efforts to obtain reimbursement from private insurers are underway and until reimbursement is in place, sales of MelaFind systems will be limited to select institutions and are expected to be minimal.
  • Cost of revenue was $0.7 million, compared with $0.9 million in the first quarter of 2014. The decrease was primarily the result of lower depreciation and other expenses, partially offset by the cost of sold MelaFind systems.
  • Selling, general and administrative expenses totaled $2.8 million, compared with $3.2 million for the first quarter of 2014. The decrease is the result of the continuing cost reduction initiatives being implemented by the Company.
  • Interest expense was $2.3 million, compared with $1,000 a year ago. Interest expense was related to the 4% Convertible Debentures and substantially consisted of $2.2 million of non-cash charges related to amortization of debt discount and deferred financing fees.  Approximately $1.7 million of interest expense was recognized as a result of the conversion of $2.3 million of Debentures into common stock during the quarter.  The change in fair value of the Company's warrant liability, which is marked to market quarterly, resulted in an expense of $1.3 million during the first quarter of 2015, compared with a benefit of $0.1 million for the first quarter of 2014.  

Michael R. Stewart, President and CEO of MELA Sciences, stated, "Our efforts aimed at establishing reimbursement for the MelaFind system will continue to accelerate over the coming months in anticipation of the issuance of the level III CPT codes in early 2016. And, we will continue working with major skin cancer institutions in an effort to establish MelaFind as an integral tool in the clinical management of melanoma."

At March 31, 2015, the Company had working capital totaling $10.0 million and cash and equivalents totaling $8.2 million. Cash and equivalents totaled $11.4 million at December 31, 2014.

About MELA Sciences, Inc.  (

MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technology for the early detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval for the United States, and CE Marking certification for the European Union for their flagship product MelaFind.

About MelaFind (

The MelaFind System utilizes innovative software-driven technology and state-of-the-art 3-D imaging to non-invasively extract data 2.5 mm below the skin surface from patient's clinically irregular pigmented moles and objectively analyzes them with proprietary algorithms.  MelaFind provides important additional perspective to physicians to help them better understand the structural disorganization of a patient's pigmented irregular moles (before cutting the skin) during the evaluation and diagnosis process for melanoma.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company's plans, objectives, expectations and intentions and may contain words such as "will," "may," "seeks," and "expects," that suggest future events or trends. These statements, including the effective date of the CPT codes for physicians' use of the MelaFind system, the Company's ability to gain Medicare Part B reimbursement from CMS and reimbursement from private insurance companies, study results, acceptance of MelaFind by practitioners and key opinion leaders and institutions, the Company's ability to expand MelaFind's use domestically and internationally and increase its visibility, the Company's ability to develop, launch and improve its products, and the Company's effectiveness in mitigating or preventing significant deficiencies or material weaknesses in its internal control over financial reporting in the future, are based on the Company's current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company's expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. The Company assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at and

  March 31,
December 31,
  (unaudited) *
Current Assets:    
Cash and cash equivalents   $ 8,233,044  $ 11,433,579
Restricted cash  100,000  -- 
Accounts receivable (net of allowance of $95,477 and $94,838 as of March 31, 2015 and December 31, 2014, respectively)  5,845  220,534
Inventory (net of reserves of $1,408,453 as of March 31, 2015 and December 31, 2014)   5,187,926  5,274,803
Prepaid expenses and other current assets  350,165  274,031
Total Current Assets  13,876,980  17,202,947
Property and equipment, net   1,620,365  1,961,376
Patents and trademarks, net  35,450  36,719
Deferred financing costs  640,981  820,775
Other assets  48,000  48,000
Total Assets  $ 16,221,776  $ 20,069,817
Current Liabilities:    
Accounts payable (includes related parties of $67,500 and $73,792 as of March 31, 2015 and December 31, 2014, respectively)  $ 1,320,274  $ 1,239,919
Accrued expenses   651,186  841,918
Deferred revenue  25,391  42,843
Warrant liability   1,833,638  499,089
Other current liabilities  54,434  61,829
Total Current Liabilities  3,884,923  2,685,598
Long Term Liabilities:    
Deferred revenue  16,420  26,500
Deferred rent  70,075  80,084
Senior secured convertible debentures (net of discount of $6,395,105 and $8,410,187 at March 31, 2015 and December 31, 2014, respectively)  4,707,410  5,000,826
Total Long Term Liabilities  4,793,905  5,107,410
Total Liabilities  8,678,828  7,793,008
Stockholders' Equity:    
Preferred stock -- $0.10 par value; authorized 10,000,000 shares: issued and outstanding: 10,279 at March 31, 2015 and 11,787 at December 31, 2014  1,028  1,179
Common stock -- $0.001 par value; authorized 50,000,000 shares:    
Issued and outstanding 7,525,146 shares at March 31, 2015 and 6,037,232 at December 31, 2014  7,525  6,037
Additional paid-in capital  197,100,186  194,562,963
Accumulated deficit  (189,565,791)  (182,293,370)
Total Stockholders' Equity   7,542,948  12,276,809
Total Liabilities and Stockholders' Equity   $ 16,221,776  $ 20,069,817
* Derived from the audited balance sheet as of December 31, 2014    
  Three months ended March 31,
  2015 2014
Net revenues  $ 81,200  $ 97,638
Cost of revenue  710,880  918,523
Gross profit  (629,680)  (820,885)
Operating expenses:    
Research and development  238,874  707,824
Selling, general and administrative  2,762,991  3,203,533
Total operating expenses  3,001,865  3,911,357
Operating loss  (3,631,545)  (4,732,242)
Other income (expenses):    
Interest income  1,126  618
Interest expense  (2,324,963)  (1,199)
Change in fair value of warrant liability  (1,334,549)  137,142
Registration rights liquidating damages  --   (3,389,940)
Other income, net  17,510  5,025
   (3,640,876)  (3,248,354)
Net loss  $ (7,272,421)  $ (7,980,596)
Basic and diluted net loss per common share  $ (1.12)  $ (1.63)
Basic and diluted weighted average number of common shares outstanding  6,471,906  4,892,641
  Three Months Ended March 31,
  2015 2014
Cash flows from operating activities:    
Net loss  $ (7,272,421)  $ (7,980,596)
Adjustments to reconcile net loss:    
Depreciation and amortization  316,243  696,800
Bad debt expense  639  700
Share-based compensation  230,062  164,168
Amortization of debt discount  2,015,082  -- 
Amortization of deferred financing costs  179,794  -- 
Change in fair value of warrant liability  1,334,549  (137,142)
Changes in operating assets and liabilities:    
Restricted cash  (100,000)  -- 
Accounts receivable  214,050  22,330
Inventory  112,914  (16,815)
Prepaid expenses and other current assets  (76,134)  414,558
Accounts payable and accrued expenses  (110,377)  (192,101)
Other current liabilities  (7,395)  (6,119)
Deferred rent  (10,009)  (10,009)
Deferred revenue  (27,532)  (76,661)
Net cash used in operating activities  (3,200,535)  (7,120,887)
Cash flows from investing activities:    
Purchases of property and equipment  --   -- 
 Net cash used in investing activities  --   -- 
Cash flows from financing activities:    
Net proceeds from private placements/public offerings  --   11,460,715
 Net cash provided by financing activities  --   11,460,715
Net (decrease)/increase in cash and cash equivalents  (3,200,535)  4,339,828
Cash and cash equivalents at beginning of period  11,433,579  3,782,881
Cash and cash equivalents at end of period  $ 8,233,044  $ 8,122,709
Supplemental Disclosure of Cash Flow Information:    
Cash paid for interest  $ 139,000  $ -- 
Supplemental Disclosure of Non-cash Investing and Financing Activities:    
Conversion of convertible preferred stock into common stock  $ 1,508,000  $ -- 
Conversion of senior secured convertible debentures into common stock  $ 2,308,498  $ -- 
Reclassification of MelaFind components from property and equipment to inventory, net  $ 26,037  $ -- 


Contact Data